752 results about "Metronidazole" patented technology

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

A pharmaceutical or cosmeceutical foamable composition for topical application of nitroimidazoles such as Metronidazole and a process of manufacturing the same is disclosed. A method of treatment of skin and scalp disorders, especially of rosacea, acne and foul smelling lesions, by dispensing nitroimidazoles such as Metronidazole in foamable composition is also disclosed.

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

The present invention provides a buffered non-flowing composition suitable for the treatment of bacterial vaginosis. The composition includes metronidazole in a concentration of about 0.50% (w / w) to about 1.50% (w / w). The metronidazole is present together with a buffer system in a physiologically tolerable medium. The buffer system provides an acidic buffered pH value for the composition in the range of about 5.0 to about 6.0. The present invention also provides for a method for inhibiting a microorganism. The method includes contacting a microorganism with an effective amount of the composition of the present invention, for a period of time effective to inhibit the microorganism. The present invention also provides for a method for treating bacterial vaginosis in a human patient. The method includes intravaginal administration to a patient in need of such treatment an effective amount of the composition the present invention. The composition is introduced into the vagina at least once a day for a time period of at least one day.

Vaginal pharmaceutical compositions are described. These compositions contain (i) an active pharmaceutical ingredient selected from the group consisting of antimicrobial imidazoles and mixtures thereof, and (ii) a polysaccharide, wherein the pH of the composition is greater than 4.25 and less than about 8. In particularly preferred compositions, the active pharmaceutical ingredient includes metronidazole and the polysaccharide includes hypromellose. These compositions can be applied to vaginal tissue for treatment of various diseases, such as bacterial vaginosis, or for prophylaxis.

Biotherapeutic compositions of a non-pathogenic bacterial strain such as M-17 and its substrains and an anaerobic bacterial antibiotic such as metronidazole, are disclosed. Further disclosed are uses of M-17 or its substrains and an anaerobic bacterial antibiotic for treating disorders caused by anaerobic bacteria, whereby such disorders include, for example, pouchitis, microbial infection, irritable bowel syndrome, inflammatory bowel disease, mucous colitis and diarrhea.

An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is a compound other than a cyclodextrin. Methods of manufacture and therapeutic use of the solution are disclosed.

Vaginal pharmaceutical compositions are described. These compositions contain (i) an active pharmaceutical ingredient selected from the group consisting of antimicrobial imidazoles and mixtures thereof, and (ii) a polysaccharide, wherein the pH of the composition is greater than 4.25 and less than about 8. In particularly preferred compositions, the active pharmaceutical ingredient includes metronidazole and the polysaccharide includes hypromellose. These compositions can be applied to vaginal tissue for treatment of various diseases, such as bacterial vaginosis, or for prophylaxis.

The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.

The invention relates to a method for treating metronidazole waste water, which comprises the following steps of: concentrating the metronidazole waste water into 1 / 3-1 / 5 of total amount, and crystallizing and filtering the concentrated metronidazole waste water at 45-100 DEG C to obtain anhydrous sodium sulfate and sodium formate; adjusting the PH to 3-6 by using sulfuric acid or formic acid, and precipitating 2-methy-5-nitro imidazole; concentrating the filter liquid to anhydrous sticky state, dissolving organic matter by using methanol or ethanol, and filtering the solution to obtain anhydrous sodium sulfate and sodium formate; merging the sodium formate and the anhydrous sodium sulfate obtained in two times, successively adding formic acid and sulfuric acid, and recovering the formic acid to obtain anhydrous sodium sulfate; and rectifying and separating the organic mixture extract of methanol or ethanol to obtain methanol or ethanol and glycol. The method for treating metronidazole waste water provided by the invention is simple and convenient to operate, the content of polluting organic matter and inorganic slats in the metronidazole waste water can be obviously reduced, environmental pollution can be preveneted, various kinds of useful organic matter and inorganic matter can be recovered, raw materials are saved, and the production cost is lowered.

The invention relates to a vagina swelling metronidazole clotrimazole suppository which comprises an active component consisting of clotrimazole, metronidazole and chlorhexidine acetate, a fat-soluble matrix and a swelling carrier. The metronidazole clotrimazole is fully swelled, so that a medicine-containing layer can be in full contact with the inner wall of the vagina to prevent medicine liquid from flowing out; the swelling metronidazole clotrimazole suppository is an inner and outer layer swelling suppository; and the active component is mixed with different matrixes to prepare an inner layer and an outer layer, so that double effects of quick release and slow release can be achieved. According to the vagina swelling metronidazole clotrimazole suppository provided by the invention, seven unique leading technologies are adopted; and furthermore, the vagina swelling metronidazole clotrimazole suppository has the beneficial effects of preventing the medicine liquid from flowing out, quickly making a response and preventing secondary infection along with long medicine working time and the like.

The invention relates to a determining method for 15 kinds of forbidden nitro imidazoles antibiotics in cosmetics. The determining method is characterized by comprising the step that a cosmetic sample is subjected to detection analysis by using a high-performance liquid chromatography-series quadrupole mass spectrometry after being subjected to supersonic extraction, high speed centrifugation and solid phase extraction. Compared with a parallelly operated standard sample of the 15 kinds of forbidden nitro imidazoles antibiotics such as metronidazole, the cosmetic sample disclosed in the invention is qualified by retention time and optimized monitoring ion pairs, is quantified by taking ions with a relatively high noise-signal ratio, a good peak form and low background interference as quantified ions, and then is subjected to external standard method quantification by using a standard curve. By utilizing the determining method, the detection speed is fast, and a result is accurate.

The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.

The invention relates to a method for measuring the residue of nitroimidazoles drugs in royal jelly, in particular to a method for measuring the residue of nitroimidazoles drugs, such as 1-(2-hydroxyethyl)-2-hydroxy-methyl-5-nitroimidazol (MNZOH), 2-methyl-5-nitroimidazole, 2-hydroxymethyl-1-methyl-5-nitroimidazole (DMZOH / HMMNI), metronidazole (MNZ), dimetridazole (DMZ), ronidazole (RNZ), 5-chloro-1-methyl-4-nitroimidazole, 5-nitrobenzimidazole, 2-(2'-hydroxyisopropyl)-1-methyl-5-nitroimidazol (IPZOH), 2-isopropyl-1-methyl-5-nitroimidazol (Ipronidazole, IPZ) and the like, in the royal jelly by the liquid chromatography-mass spectrometry / mass spectrometer (LC-MS / MS). The method comprises the following steps: precipitating protein by methanol; extracting; further carrying out the purification using HLB (hydrophilic-lipophilic balance) and C18 solid-phase extraction (SPE) columns; and measuring the residue by LC-MS / MS. The invention has the characteristics of high specificity, high sensitivity and accurate results, and allows for the measurement of both the nitroimidazoles original drugs and the metabolites thereof; the lower limit of detection (10 mug / kg) in the method meets the existing requirements for the residue of nitroimidazoles drugs in the royal jelly at home and aboard; the recovery rate ranges from 70.7% to 105.0%; and the relative standard deviation (RSD) is lower than 12.7%.

The invention provides a flushing fluid for surgery, which comprises solute and solvent, wherein the solute is one or two selected from cellulose glycollic ether, carboxymethyl chitosan or carboxymethyl chitosan, the solvent being water for injection, physiological saline solution, sodium chloride flushing fluid, mannitol flushing fluid, glucose flushing fluid, chlorhexidine flushing fluid, gentamicin physiological saline flushing fluid, active iodine flushing fluid, benzalkonium bromide flushing fluid, aminoacetic acid flushing fluid, metronidazole flushing fluid or physiological equilibrium liquid comprising phosphates cushioning liquid, NaHCO3, sodium gluconate and mannitol.

The vagina effervescent tablet has the salt or ester of clindamycin and metronidazole as active component and is prepared via a common tablet making process. The present invention features that the said effervescent tablet contains hydroxypropyl methyl cellulose as adhesive. Compared with conventional effervescent tablet, the present invention has the advantages of greater foam amount, fine and lasting foams, homogeneous distribution of effective medicine component, long duration, raised medicine curative effect, simple preparation process, stable quality and being suitable for industrial production.

Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.

Disclosed is an ointment using the salts or esters of clindamycinum and metronidazole as the active constituents, the constituents of the ointment include (by weight percent): clindamycinum or its medicinal salts or its esters 0.25-5%, metronidazole 0.2-4%, oleaginous base 10-40%, water soluble base 5-50%, and balancing water, wherein the oleaginous base is selected from stearinic acid, glyceryl monostearate, paraffin wax, fluid wax, Vaseline, lanoline, cetyl alcohol, stearyl alcohol, Span series, bee wax, animal or vegetable fat, the water soluble base is selected from glycerin, propylene glycol, sorbitol, polyethylene glycol series, Tween series, sodium dodecylsulfate, dimethyl sulfoxide, triethanolamine, and ethanol.

The invention relates to an F-1,2,3-triazole ring-polyethylene glycol-metronidazole compound which has the following structural general formula: L is ethyl or polyethylene glycol with the following structure: n is equal to 0, 1, 2 or 3; M is a triazole ring with the following structure: or, N is ethyl or polyethylene glycol with the following structure; n is equal to 0, 1, 2 or 3; and A is 19F or18F. Under a changeless condition that the invention keeps the metronidazole as a targeting base group, the polyethylene glycol is introduced to modify and change the molecular structure of a medicine, and the aims of improving medicine dynamics and pharmacodynamical properties and increasing the curative effect of the medicine are achieved. The triazole ring, a PEG base group, 2- metronidazole and 18 / 19F nuclide are connected by a click method, and a series of novel F-triazole ring-PEG-metronidazole derivatives are designed and synthesized. The nitro imidazole derivatives can quicken removing from normal tissues by lowering fat solubility so as to enhance a target / non-target ratio and is used for the development research of tumours, cardiac muscles or brain anoxia.

The invention relates to compound emulsifiable paste for treating acne and a preparation method thereof, in particular to a medicament for treating acne and a preparation method thereof. The compound emulsifiable paste solves the problems of long treatment course and skin oxidation, dim skin and formation of color spots in the healing process in the conventional medicament for treating the acne. The compound emulsifiable paste is prepared from clindamycin hydrochloride, metronidazole, vitamin A, vitamin C, an emulsifying agent, stearic acid, albolene, glycerol monostearate, lanolinum, glycerol and purifying water. The preparation method comprises the following steps of: adding the vitamin A into uniform solution prepared from the stearic acid, the albolene, the glycerol monostearate and the lanolinum to obtain an oil phase; dissolving the glycerol and the emulsifying agent into the purifying water, adding the clindamycin hydrochloride, the metronidazole and the vitamin C, and stirring uniformly to obtain a aqueous phase; and adding the oil phase into the aqueous phase, stirring, homogenizing and standing the mixture to obtain the compound emulsifiable paste for treating the acne. The treatment period of the compound emulsifiable paste is between 14 and 24 days, skin is bright and clean after healing, and the compound emulsifiable paste can treat the acne, seborrheic dermatitis, acne rosacea and folliculitis.

The invention provides a disinfectant gellant for gynaecology external use and its preparation method, which relates to a pharmaceutical composition for external use to treat gynaecological vaginitis. The disinfectant gellant for gynaecological external use comprises a gel matrix, a penetration enhancer, a bactericide, a surfactant, essence, ethanol and purified water as balance. Each 1000 ml of the disinfectant gellant for gynaecological external use comprises 10% to 12% of gel matrix, penetration enhancer, bactericide, surfactant, essence, ethanol in proportion. The present invention has the advantages that the composite bactericide is added with the penetration enhancer based on chlorhexidine acetate and metronidazole complex formulation. Natural borneol is taken as the penetration enhancer, thereby the invention has double effects of penetrating promotion and sterilization. The invention has the characteristics of wide spectrum, strong sterilization capability and strong nursing capability, as well as the invention employs the gallant for external use.

The invention relates to a method for treating waste water from production of metronidazole. The steps of the method are as follows: adding alkali in metronidazole process waste water to adjust pH value and after evaporation, sending the metronidazole process waste water to a waste water adjusting tank; allowing imidazole process waste water and nitration process waste water to enter the waste water adjusting tank respectively through a grating; after mixture as well as water-quality and water-quantity adjustment by the waste water adjusting tank, sending the imidazole process waste water and the nitration process waste water to an electrolyzer for electrochemical catalysis water treatment; adding lime milk in the effluent of the electrolyzer to adjust pH value, sequentially removing ammonia-nitrogen by a neutralization aeration tank, adding flocculant, separating by a coagulative precipitation tank, and allowing supernatant water to enter a facultative tank for anaerobic degradation; and conducting oxic degradation by a biomembrane aeration tank and precipitation by a secondary precipitation tank on the effluent of the facultative tank for standardized discharge. Adopting a electrochemical catalysis water treatment technology for pretreating waste water, the method effectively eliminates the biotoxicity of the waste water, lowers the pollutant concentration of the waste water and greatly improves the biodegradability of the waste water, thus laying foundation for standardized biochemical treatment. The method is simple in technology and convenient in operation.

The invention discloses metronidazole ophthalmic gel and a preparation method and an application thereof, which belong to the technical field of medicine. Metronidazole serving as a related medicinal active ingredient is prepared into ophthalmic gel for the first time. The metronidazole ophthalmic gel is applied to prevention and treatment of blepharitis ciliaris, hordeolum and conjunctivitis caused by worm acarus infection, and a dry eye syndrome caused by meibomian gland dysfunction, and is applied to prevention and treatment of infection of acanthamoeba protozoan and anaerobic bacteria in the wearing process of corneal contact lenses. The metronidazole ophthalmic gel consists of metronidazole and a pharmaceutically-acceptable vector, and the using amount of metronidazole in every 100g of the metronidazole ophthalmic gel is 0.1-3.0g by weight.

Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions / afflictions, notably rosacea.

A Shuangzuotai suppository is prepared proportionally from metronidazole, mycosporin, chlorhexidine acetate, matrix, cotton suppository saturated by said matrix, and a tubular band made of PVC or PE.

The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.

The present invention relates to a pharmaceutical composition, in particular a composition formulated for enema administration, wherein the composition comprises metronidazole or a pharmacologically acceptable derivative thereof in an amount to effectively treat both acute and chronic pouchitis and / or proctitis.

The invention belongs to the fields of biomedicine and reagent detection, and relates to a human leukocyte antigen gene detection kit and application thereof in screening metronidazole-induced adverse drug reactions of skin. The kit contains a reagent for detecting human leukocyte antigen gene HLA-B*39:01 nucleic acid or protein, and amplification primers or a labeled probe of the human leukocyte antigen gene or a specific antibody containing the human leukocyte antigen. The HLA-B*39:01 gene can be used as a labeled gene for predicting metronidazole-induced epispasis. The detection kit can be used for further preparing or evaluating a metronidazole-induced epispasis screening kit, thereby providing valuable reference data for instructing clinical medication, and reducing the possibility of metronidazole-induced epispasis; or the detection kit can also be used for preparing or evaluating therapeutic drugs and especially targeted drugs for metronidazole-induced epispasis, thereby preventing the interactions between the drugs and metronidazole or metabolites thereof in disease development.

The invention discloses a composition for treating chicken proventriculitis and a preparation method thereof, which aim to provide a composition for treating the infection of chicken proventriculitis by addressing both symptoms and root causes and a preparation method thereof. The composition comprises the following components in percentage by weight: 1 to 10 percent of florfenicol, 5 to 15 percent of metronidazole, 1 to 6 percent of ranitidine hydrochloride, 2 to 15 percent of taurine and the balance of glucosum anhydricum. In the composition, aiming at pathogeny, the florfenicol and the metronidazole which serve as antimicrobial medicaments are adopted to kill anaerobic bacteria and helicobacter pylori effectively, reduce the occurrence probability of the tolerance of pathogenic bacteria and improve the sensitivity; the ranitidine hydrochloride inhibits the gastric acid effect and reduces the injury of gastric acid to inflamed glandular stomachs; and the taurine has the obvious effect of inflammation resistance, has no irritation on gastrointestinal tracts, and has the effect of diminishing inflammation quickly. Aiming at the pathogeny and diseases, the medicaments are combined, so that the composition can address both symptoms and root causes effectively on antipathogen and clinical symptoms thereof and treat the chicken proventriculitis effectively.

The invention discloses a metronidazole production method, belonging to the technical field of chemical synthesis. The method sequentially comprises the processes of mixed acid preparation, hydroxylation reaction, formic acid recovery, first neutralization, second neutralization, third neutralization and refining. The process of formic acid recovery specifically comprises the steps of transferring the hydroxylation liquid obtained by the hydroxylation reaction into a distillation kettle, controlling the temperature at 65-90 DEG C and the vacuum degree at (-0.085)-(-0.095)MPa, and performing reduced-pressure distillation to obtain formic acid. According to the metronidazole production method disclosed by the invention, the formic acid is recovered in a metronidazole production process, the usage amount of alkali and the discharge amount of wastewater are reduced, and the production cost is lowered. Meanwhile, the method disclosed by the invention improves the reaction yield of a final product by adjusting the reaction process and parameters.